Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.15
+0.10 (1.24%)
Jan 21, 2025, 4:00 PM EST - Market closed
Zevra Therapeutics Employees
As of December 31, 2023, Zevra Therapeutics had 69 total employees, including 65 full-time and 4 part-time employees. The number of employees increased by 33 or 91.67% compared to the previous year.
Employees
69
Change (1Y)
33
Growth (1Y)
91.67%
Revenue / Employee
$354,913
Profits / Employee
-$1,299,478
Market Cap
435.01M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ZVRA News
- 13 days ago - Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market - CNBC
- 5 weeks ago - Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics Announces Organizational Changes - GlobeNewsWire
- 2 months ago - Zevra Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C - GlobeNewsWire
- 2 months ago - Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting - GlobeNewsWire
- 2 months ago - Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13 - GlobeNewsWire